drugset / Trial / NCT00104091

Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors

NCT00104091 ↗

Phase 2 Completed 56 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Immunotoxin therapy may be effective in treating malignant glioma. Immunotoxins can locate tumor cells and kill them without harming normal cells.

Timeline

Start
2004-12
Primary completion
2007-04
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject TP-38 Protein / enzyme biologic 100 ng/ml —
Subject TP-38 Protein / enzyme biologic 40 ml —

Indications